文献速递胸部肿瘤放疗放疗物理与技术

三维间质高剂量率近距离放疗联合区域转移淋巴结调强放疗治疗局部晚期周围型非小细胞肺癌:2期临床试验5年随访结果

Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy With Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-25

这项2期单臂开放标签试验纳入83例局部晚期周围型非小细胞肺癌患者,接受三维间质高剂量率近距离放疗联合区域转移淋巴结调强放疗,中位随访53.7个月,最终分析75例。中位总生存38.0个月,5年总生存率44.5%,5年局部无复发生存率79.2%,无晚期≥2级不良事件,主要失败模式为远处转移。

要点

  • 5年总生存率44.5%,中位总生存38.0个月
  • 5年局部无复发生存率79.2%,远处转移为主要失败模式
  • 无晚期≥2级放疗相关不良事件,急性≥3级食管炎发生率5.3%

核心结论

  • 三维间质高剂量率近距离放疗联合区域转移淋巴结调强放疗治疗局部晚期周围型非小细胞肺癌显示出显著的总生存获益和低毒性率。
  • 作者建议开展3期试验进一步验证这些发现。

研究设计与样本

  • 2期单臂开放标签临床试验,纳入83例局部晚期周围型非小细胞肺癌患者,中位随访53.7个月(范围4.3-120.4个月)。
  • 所有合格患者接受三维间质高剂量率近距离放疗联合区域转移淋巴结调强放疗,主要终点为总生存。

主要发现

  • 最终分析纳入75例患者,其中女性19例(25.3%)、男性56例(74.7%),中位年龄64岁(范围44-80岁),IIIA期34例(45.3%)、IIIB期41例(54.7%)。
  • 末次随访时32例(42.7%)患者存活,中位总生存38.0个月,5年总生存率44.5%(95%CI 33.8%-58.6%)。
  • 5年局部无复发生存率79.2%(95%CI 68.5%-91.5%),无复发生存率73.6%(95%CI 61.5%-88.1%),远处无转移生存率50.3%(95%CI 38.3%-66.1%)。
  • 主要失败模式为远处转移,占75例患者的40%(30/75),占所有失败事件的65.2%(30/46)。
  • 2例(2.7%)发生1级急性肺炎,11例(14.7%)发生2级急性食管炎,4例(5.3%)发生3级急性食管炎,未观察到晚期放疗相关≥2级不良事件。

临床怎么用

  • 作者建议在3期试验中进一步评估该方案以证实这些发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to reveal the 5-year clinical outcomes of 3-dimensional (3D) interstitial high-dose-rate (HDR) brachytherapy with regional metastatic lymph node intensity modulated radiation therapy (IMRT) for locally advanced peripheral non-small cell lung cancer (NSCLC), which has been shown to have low toxicity and improved 2-year survival rates in patients with this disease. METHODS AND MATERIALS: In this phase 2, single-arm, open-label clinical trial, 83 patients with locally advanced peripheral NSCLC were enrolled (median follow-up [range], 53.7 [4.3-120.4] months). All eligible patients received 3D interstitial HDR brachytherapy with regional metastatic lymph node IMRT. The primary endpoint was overall survival (OS). Secondary endpoints were local recurrence-free survival, regional recurrence-free survival, progression-free survival, distant metastasis-free survival, toxicities, and quality of life. RESULTS: The final analysis included 75 patients (19 [25.3%] females, 56 [74.7%] males; median [range] age, 64 [44-80] years; stage IIIA, 34 [45.3%]; stage IIIB, 41 [54.7%]). At the latest follow-up, 32 (42.7%) patients had survived. The median OS was 38.0 months (5-year OS, 44.5%; 95% confidence interval [CI], 33.8%-58.6%). Local recurrence-free survival, recurrence-free survival, and distant metastasis-free survival at 5 years were 79.2% (95% CI, 68.5%-91.5%), 73.6% (95% CI, 61.5%-88.1%), and 50.3% (95% CI, 38.3%-66.1%), respectively. The dominant failure pattern was distant disease, corresponding to 40% (30 of 75) of patients and 65.2% (30 of 46) of all failures. Two (2.7%) patients developed grade 1 acute pneumonitis. Grade 2 and 3 acute esophagitis occurred in 11 (14.7%) and 4 (5.3%) patients, respectively. No late radiation-related grade ≥2 late adverse events were observed. CONCLUSIONS: 3D interstitial HDR brachytherapy with regional metastatic lymph node IMRT for locally advanced peripheral NSCLC shows significant OS and has a low toxicity rate. Additional evaluation in a phase 3 trial is recommended to substantiate these findings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Xiang L, Ren PR, Li HX, et al. Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy With Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35901979. doi:10.1016/j.ijrobp.2022.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。